Nature:“长的非编码RNAs”在去势抵抗性前列腺癌中上调

2013-09-04 Nature中文网 Nature中文网

几个“长的非编码RNAs”(lncRNAs) 已知在前列腺癌中过度表达。Michael Rosenfeld及同事研究了这些“长的非编码RNAs”中的两个的机制功能和生物功能,它们分别是PRNCR1 和 PCGEM1。二者都被发现依赖于特定的翻译后修饰与雄性激素受体(AR)发生相互作用,增强与AR结合在一起的增强子向目标基因启动子的成环作用(looping),导致基因表达增强。它们还增强前列腺癌细胞

几个“长的非编码RNAs”(lncRNAs) 已知在前列腺癌中过度表达。Michael Rosenfeld及同事研究了这些“长的非编码RNAs”中的两个的机制功能和生物功能,它们分别是PRNCR1 和 PCGEM1。二者都被发现依赖于特定的翻译后修饰与雄性激素受体(AR)发生相互作用,增强与AR结合在一起的增强子向目标基因启动子的成环作用(looping),导致基因表达增强。它们还增强前列腺癌细胞由AR-介导的增殖,并且是一个前列腺癌异种移植小鼠模型的肿瘤生长所需要的。PRNCR1 和 PCGEM1在“去势抵抗性前列腺癌”细胞系中被上调。这篇文章中所揭示的lncRNAs在前列腺癌中的调控作用也许能为新的治疗方法开辟道路。

原始出处:

Yang L, Lin C, Jin C, Yang JC, Tanasa B, Li W, Merkurjev D, Ohgi KA, Meng D, Zhang J, Evans CP, Rosenfeld MG.lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs.Nature. 2013 Aug 29;500(7464):598-602.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1665901, encodeId=a1e1166590106, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Sat Aug 09 11:08:00 CST 2014, time=2014-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743408, encodeId=9d641e43408e2, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Thu Mar 06 21:08:00 CST 2014, time=2014-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005403, encodeId=6c1b2005403fc, content=<a href='/topic/show?id=d09f155461e' target=_blank style='color:#2F92EE;'>#RNAs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15546, encryptionId=d09f155461e, topicName=RNAs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sat Apr 26 09:08:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879656, encodeId=750c18e96561a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jan 10 22:08:00 CST 2014, time=2014-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342079, encodeId=23c013420e949, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37234, encryptionId=da143e23485, topicName=去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Fri Sep 06 04:08:00 CST 2013, time=2013-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584610, encodeId=079015846101e, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Fri Sep 06 04:08:00 CST 2013, time=2013-09-06, status=1, ipAttribution=)]
    2014-08-09 yige2012
  2. [GetPortalCommentsPageByObjectIdResponse(id=1665901, encodeId=a1e1166590106, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Sat Aug 09 11:08:00 CST 2014, time=2014-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743408, encodeId=9d641e43408e2, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Thu Mar 06 21:08:00 CST 2014, time=2014-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005403, encodeId=6c1b2005403fc, content=<a href='/topic/show?id=d09f155461e' target=_blank style='color:#2F92EE;'>#RNAs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15546, encryptionId=d09f155461e, topicName=RNAs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sat Apr 26 09:08:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879656, encodeId=750c18e96561a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jan 10 22:08:00 CST 2014, time=2014-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342079, encodeId=23c013420e949, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37234, encryptionId=da143e23485, topicName=去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Fri Sep 06 04:08:00 CST 2013, time=2013-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584610, encodeId=079015846101e, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Fri Sep 06 04:08:00 CST 2013, time=2013-09-06, status=1, ipAttribution=)]
    2014-03-06 d830384
  3. [GetPortalCommentsPageByObjectIdResponse(id=1665901, encodeId=a1e1166590106, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Sat Aug 09 11:08:00 CST 2014, time=2014-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743408, encodeId=9d641e43408e2, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Thu Mar 06 21:08:00 CST 2014, time=2014-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005403, encodeId=6c1b2005403fc, content=<a href='/topic/show?id=d09f155461e' target=_blank style='color:#2F92EE;'>#RNAs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15546, encryptionId=d09f155461e, topicName=RNAs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sat Apr 26 09:08:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879656, encodeId=750c18e96561a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jan 10 22:08:00 CST 2014, time=2014-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342079, encodeId=23c013420e949, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37234, encryptionId=da143e23485, topicName=去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Fri Sep 06 04:08:00 CST 2013, time=2013-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584610, encodeId=079015846101e, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Fri Sep 06 04:08:00 CST 2013, time=2013-09-06, status=1, ipAttribution=)]
    2014-04-26 dzx0922889
  4. [GetPortalCommentsPageByObjectIdResponse(id=1665901, encodeId=a1e1166590106, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Sat Aug 09 11:08:00 CST 2014, time=2014-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743408, encodeId=9d641e43408e2, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Thu Mar 06 21:08:00 CST 2014, time=2014-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005403, encodeId=6c1b2005403fc, content=<a href='/topic/show?id=d09f155461e' target=_blank style='color:#2F92EE;'>#RNAs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15546, encryptionId=d09f155461e, topicName=RNAs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sat Apr 26 09:08:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879656, encodeId=750c18e96561a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jan 10 22:08:00 CST 2014, time=2014-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342079, encodeId=23c013420e949, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37234, encryptionId=da143e23485, topicName=去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Fri Sep 06 04:08:00 CST 2013, time=2013-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584610, encodeId=079015846101e, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Fri Sep 06 04:08:00 CST 2013, time=2013-09-06, status=1, ipAttribution=)]
    2014-01-10 liye789132251
  5. [GetPortalCommentsPageByObjectIdResponse(id=1665901, encodeId=a1e1166590106, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Sat Aug 09 11:08:00 CST 2014, time=2014-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743408, encodeId=9d641e43408e2, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Thu Mar 06 21:08:00 CST 2014, time=2014-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005403, encodeId=6c1b2005403fc, content=<a href='/topic/show?id=d09f155461e' target=_blank style='color:#2F92EE;'>#RNAs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15546, encryptionId=d09f155461e, topicName=RNAs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sat Apr 26 09:08:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879656, encodeId=750c18e96561a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jan 10 22:08:00 CST 2014, time=2014-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342079, encodeId=23c013420e949, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37234, encryptionId=da143e23485, topicName=去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Fri Sep 06 04:08:00 CST 2013, time=2013-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584610, encodeId=079015846101e, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Fri Sep 06 04:08:00 CST 2013, time=2013-09-06, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1665901, encodeId=a1e1166590106, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Sat Aug 09 11:08:00 CST 2014, time=2014-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743408, encodeId=9d641e43408e2, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Thu Mar 06 21:08:00 CST 2014, time=2014-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005403, encodeId=6c1b2005403fc, content=<a href='/topic/show?id=d09f155461e' target=_blank style='color:#2F92EE;'>#RNAs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15546, encryptionId=d09f155461e, topicName=RNAs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sat Apr 26 09:08:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879656, encodeId=750c18e96561a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jan 10 22:08:00 CST 2014, time=2014-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342079, encodeId=23c013420e949, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37234, encryptionId=da143e23485, topicName=去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Fri Sep 06 04:08:00 CST 2013, time=2013-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584610, encodeId=079015846101e, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Fri Sep 06 04:08:00 CST 2013, time=2013-09-06, status=1, ipAttribution=)]

相关资讯

2013年国家自然科学基金医学类肿瘤学获批最多

医学类独占鳌头项目数6985项,占总项目数的25%,获批项目金额也是最高,达到367041.2万元,占总金额23.3%。 从获批情况来看,肿瘤学最多,获批1531项,获批金额达79289.50。占获批总数和获批金额总数分别是22%,21.6% 表:医学类获批项目情况 学科名 项目数

Genome Res:可以有效寻找癌症、糖尿病基因的预测模型

来自延世大学李仁锡教授,利用'机能遗传子网络'预测模型,开发的可以有效地发掘调解复杂疾患遗传子的新方法。 此次研究是通过与欧洲分子生物学研究所的Lehner博士,德克萨斯州立大学的Marcotte博士,加拿大多伦多大学的Fraser博士的国际共同研究所进行的研究,也是得到教科部及韩国研究财团的'优秀研究中心(S/ERC)育成事业'与'一半研究者支援事业'支援的随性研究。 李仁锡教授研究组利用'

Lancet Oncol:TERT启动子UTSS区域高度甲基化是儿童脑肿瘤进展的预测标记

研究要点:TERT启动子甲基化可作为儿童恶性脑肿瘤的生物标记和预后判断标记。在儿童恶性脑肿瘤中,当肿瘤从低级别向高级别转化时,UTSS甲基化增加。TERT启动子UTSS区域的高度甲基化与肿瘤中TERT的表达相关。在儿科神经系统肿瘤领域中,鉴定得到对恶性疾病有提示意义的生物标记是十分重要的方面。这有助于建立评估疾病出现进展的方法。加拿大多伦多大学的Pedro Castelo-Branco等为了探

Nature:科学家发现30种常见癌症DNA秘密 助开发新疗法

  研究人员已解开30种最常见癌症的DNA秘密,使我们离了解它们的起因更近一步。癌症是由DNA突变造成的。 科学家有望了解肿瘤DNA的遗传密码模式,例如由吸烟造成的肺癌等。但其他原因令人吃惊,例如科学家认为一种有助于我们抵抗传染病的蛋白质造成癌症等。每种癌症有至少两个遗传密码模式,但乳腺癌但有5个,肝癌有6个。 据国外媒体9月2日报道,英国科学家在抗癌的道路上有了一项意义深

Nat Biotechnol:科学家利用干细胞制造大量可靶向肿瘤的免疫细胞

近日,纪念斯隆-凯特林癌症中心的科学家发明了一种利用干细胞制造出大量可杀死小鼠体内肿瘤细胞的人免疫细胞的新技术。该技术或能让癌症免疫疗法这种通过激活免疫系统来消灭肿瘤的治疗方法更容易获得实施。相关研究论文刊登在了近期出版的Nature Biotechnology杂志上。【原文下载】 大多数癌症免疫疗法需要从病人血液中分离出T细胞这种免疫细胞。但是,能够杀死特定肿瘤细胞而不

自闭症可能与肿瘤基因相关

从表面上来看,自闭症和肿瘤是两种风马牛不相及的疾病。然而,研究这两种疾病的科学家们却意外地得出了同一个惊人的发现:某些自闭症患者携带有突变型的癌症或肿瘤基因,很可能正是这些基因突变导致了他们的脑部功能紊乱。 PTEN基因的突变可引发乳腺、结肠、甲状腺以及其他器官发生癌症。在携带该突变的儿童中,有10%患有自闭症。而在携带可导致某些类型的脑癌、肾癌以及若干器官(包括脑部)大型肿瘤的突变基因的儿